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Background/Aims: We evaluated the clinical features of ciprofloxacin-resistant Proteus mirabilis bacteremia and
risk factors for ciprofloxacin resistance.
Methods: From October 2000 to July 2009, 37 patients with clinically significant P. mirabilis bacteremia were
identified and data from patients with ciprofloxacin-resistant and ciprofloxacin-susceptible P. mirabilis bacteremia
were compared.
Results: The most common underlying diseases were neurologic disease (37.8%) and solid tumors (29.7%). The
most common site of infection was the urinary tract (35.1%). Ten of the 37 patients (27.0%) were infected with
ciprofloxacin-resistant isolates, and univariate analysis revealed a significant relationship between ciprofloxacin-
resistant P. mirabilis bacteremia and neurologic disease, recent operation, L-tube insertion, percutaneous tube
use, and extended-spectrum β-lactamase (ESBL) production (all p < 0.05). ESBL was detected in six of 10 (60%)
ciprofloxacin-resistant isolates, while only three of 27 (11%) ciprofloxacin-susceptible isolates produced ESBL (p =
0.005). In a logistic regression analysis, ESBL production remained a significant factor associated with
ciprofloxacin resistance, after adjusting for other variables.
Conclusions: These data indicate a close association between ciprofloxacin resistance and ESBL-production in
P. mirabilis bacteremia. This association is particularly troublesome because the therapeutic options for serious
infections caused by ESBL-producing P. mirabilis are severely restricted. (Korean J Intern Med 2011;26:89-93)
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INTRODUCTION
Proteus mirabilis can cause a variety of community- or
hospital-acquired infections, including urinary tract, intra-
abdominal, and bloodstream infections [1,2]. Antimicrobial
resistance has been reported increasingly for this species,
and increased resistance to extended-spectrum
cephalosporins due to the production of extended-spec-
trum β-lactamases (ESBLs) has become of great concern
[1,3,4]. Consequently, carbapenem has emerged as the
agent of choice for the treatment of serious infections
caused by ESBL-producing pathogens. Fluoroquinolones
may be an effective alternative antimicrobial therapy.
However, similar to Escherichia coli and Klebsiella pneu-
moniae, the incidence of ciprofloxacin resistance in P.
mirabilis isolates is increasing [5,6].90 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
Although the occurrence of ciprofloxacin resistance in
E. coli and K. pneumoniae isolates is well-established, lit-
tle is known of the epidemiology of P. mirabilis bac-
teremia caused by ciprofloxacin-resistant isolates. Thus, in
this study, we evaluated the clinical features of
ciprofloxacin-resistant P. mirabilis bacteremia to clarify
the risk factors for ciprofloxacin resistance in P. mirabilis
isolates causing bacteremia.
METHODS
The database in our clinical microbiology laboratory
(Samsung Medical Center, Seoul, Korea; a 1,950-bed, ter-
tiary-care university hospital and referral center) was
reviewed to identify patients > 16 years of age diagnosed
with P. mirabilis bacteremia from October 2000 to July
2009. Only the first episode for each patient was included
in the analysis. Antibiotic susceptibility was tested using
the VITEK II automated system (bioMérieux, Hazelwood,
MO, USA) using the standard modified broth microdilu-
tion method. Minimum inhibitory concentration (MIC)
breakpoints and quality control protocols were used
according to standards established by the Clinical and
Laboratory Standards Institute [7]. For the purposes of
this study, isolates showing in vitro resistance to cefo-
taxime, ceftriaxone, or ceftazidime were classified as
ESBL-producing organisms. Strains showing an ‘interme-
diate’ result to the tested antibiotics were considered resis-
tant.
We compared the clinical features of patients with
ciprofloxacin-resistant and ciprofloxacin-susceptible P.
mirabilis bacteremia. The data collected included age,
gender, underlying disease, primary site of infection,
acquisition site, and antimicrobial regimen. The presence
of the following comorbid conditions was also document-
ed: recent operation, corticosteroid use, indwelling uri-
nary catheter, L-tube insertion, percutaneous tube use,
prior invasive procedure, and prior use of antibiotics.
Nosocomial acquisition of infection was defined as an
infection that occurred > 48 hours after hospital admis-
sion, while infections diagnosed within the first 48 hours
of hospitalization were classified as community-onset
infection, based on the time the culture samples were
obtained. Because many cases of Proteus bacteremia that
are present or incubating on admission to the hospital are
nonetheless healthcare-associated, we refer to non-noso-
comial bacteremia as community-onset rather than com-
munity-acquired. Community-onset infection was further
classified as community-associated and healthcare-associ-
ated, as previously suggested [8]. The site of infection was
determined by physicians, based on the isolation of P.
mirabilis from the presumed portal of entry and clinical
evaluation.
Student's t test was used to compare continuous vari-
ables, and χ
2 or Fisher's exact tests were used to compare
categorical variables. A logistic regression analysis was
performed to evaluate ESBL production as a factor associ-
ated with ciprofloxacin resistance. The odds ratio (OR)
and 95% confidential interval (CI) were calculated. All p
values were two-tailed, and p < 0.05 was considered to
indicate statistical significance.
RESULTS
Thirty-seven patients with P. mirabilis bacteremia were
identified. Their demographic and clinical characteristics
are shown in Table 1. The most common underlying dis-
eases were neurologic diseases (38%) and solid tumors
(30%). The most common site of infection was the urinary
tract (35%). Ten (27%) of the 37 patients were infected
with ciprofloxacin-resistant isolates and nine (24%) were
infected with ESBL-producers. Among the 27 patients
Table 1. Clinical characteristics of 37 patients with
Proteus mirabilis bacteremia
Characteristics No. of patients (%)
Age, yr (mean ± SD) 62.4 ± 17.8
Female 22 (59.5)
Acquisition site
Community-associated 17 (45.9)
Healthcare-associated 10 (27.0)
Nosocomial infection 10 (27.0)
Underlying disease
Neurologic disease 14 (37.8)
Solid tumor 11 (29.7)
Diabetes mellitus 6 (16.2)
Cardiovascular disease 3 (8.1)
Renal disease 3 (8.1)
Primary site of infection
Primary bacteremia 12 (32.4)
Urinary tract infection 13 (35.1)
Intra-abdominal infection 8 (21.6)
Pneumonia 4 (10.8)
Extended-spectrum β-lactamase production 9 (24.3)
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determined to have community-onset infections, five
(19%) had ciprofloxacin-resistant bacteremia. Among the
ten patients identified as having a nosocomial-acquired
infection, five (50%) had ciprofloxacin-resistant bac-
teremia (p= 0.094).
Risk factors associated with ciprofloxacin-resistant P.
mirabilis are listed in Table 2. Univariate analysis
revealed a significant relationship between ciprofloxacin-
resistant P. mirabilis bacteremia and neurologic disease,
recent operation, L-tube insertion, percutaneous tube use,
and ESBL production (all p< 0.05). ESBL was detected in
six (60%) of ten ciprofloxacin-resistant P. mirabilis iso-
lates. In comparison, only three (11%) of 27 ciprofloxacin-
susceptible P. mirabilis isolates were ESBL producers.
ESBL production was significantly associated with
ciprofloxacin resistance among P. mirabilis isolates caus-
ing bacteremia (OR, 12.00; 95% CI, 2.10 to 68.6; p =
0.005). In a logistic regression analysis, ESBL production
remained a significant factor associated with ciprofloxacin
resistance, after adjusting for nosocomial infection, neuro-
logic disease, or recent operation (OR, 13.93; 95% CI, 1.04
to 186.07; p= 0.046).
Four (40%) of ten patients with ciprofloxacin-resistant
bacteremia received inappropriate initial antimicrobial
therapy, while three (11%) of 27 patients with
ciprofloxacin-susceptible bacteremia received inappropri-
ate initial antimicrobial therapy (p = 0.069). Of 32
patients whose outcomes could be evaluated, eight (25%)
died within 30 days; no significant difference was found
between ciprofloxacin-resistant (1/9, 11%) and -suscepti-
ble (7/23, 30%) patients (p= 0.386). When factors associ-
ated with mortality were evaluated, solid tumor was found
to be the only significant factor associated with mortality
(p= 0.005).
DISCUSSION
This study revealed that neurologic disease, recent oper-
ation, L-tube insertion, and percutaneous tube were sig-
nificant risk factors associated with the development of
bacteremia caused by ciprofloxacin-resistant P. mirabilis.
Ciprofloxacin resistance in K. pneumoniae has been
reported to be closely associated with ESBL production
[9]. Several studies have examined the relationship
between quinolone resistance and ESBL production in E.
coli and K. pneumoniae [10,11]. Ciprofloxacin-resistant
Enterobacter bacteremia is closely associated with broad-
spectrum cephalosporin resistance [12]. Consistent with
the latter study, we also observed a close association of
ciprofloxacin-resistant P. mirabilis bacteremia with
broad-spectrum cephalosporin resistance conferred by
ESBL.
This association is of great concern because ESBL-pro-
Table 2. Factors associated with ciprofloxacin resistance in Proteus mirabilis isolates causing bacteremia
Ciprofloxacin-resistant (n = 10) Ciprofloxacin-susceptible (n = 27) p value
Male gender 6 (60.0) 9 (33.3) 0.258
Nosocomial infection 5 (50.0) 5 (18.5) 0.094
Underlying diseases
Solid tumor 1 (10.0) 10 (37.0) 0.224
Neurologic disease 7 (70.0) 7 (25.9) 0.023
Renal disease 0 (0) 3 (11.1) 0.548
Diabetes mellitus 2 (20.0) 4 (14.8) 0.653
Comorbid conditions
Recent operation 5 (50.0) 0 (0) 0.001
Corticosteroid use 3 (30.0) 3 (11.1) 0.166
Central venous catheterization 2/8 (25.0) 1/18 (5.6) 0.215
Indwelling urinary catheter 2 (20.0) 1 (3.7) 0.172
L-tube 3/8 (37.5) 0/18 (0) 0.022
Percutaneous tube 3/8 (37.5) 0/18 (0) 0.022
Prior invasive procedure 2/8 (25.0) 0/18 (0) 0.086
Prior use of antibiotics 3/8 (37.5) 1/18 (5.6) 0.072
ESBL production 6 (60.0) 3 (11.1) 0.005
Values are presented as number (%).  
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ducing P. mirabilis isolates are usually resistant to peni-
cillins and cephalosporins. Thus, ciprofloxacin resistance
severely limits already restricted treatment options.
Additionally, the marked increase in the incidence of
ESBL-producing P. mirabilis isolates in recent years is of
great concern [1,3,13]. Although carbapenems remain the
most effective option for treating serious infection caused
by ESBL-producing P. mirabilis, the increasing use of car-
bapenems has been paralleled by the rapid emergence of
carbapenem resistance in nosocomial pathogens [14,15].
What is the explanation for the coexistence of these two
resistance mechanisms in Gram-negative bacilli? The
relationship between ciprofloxacin resistance and ESBL
production may be due to the interplay between prior
heavy antibiotic use and conditions favoring patient-to-
patient transfer of multidrug-resistant organisms, as
described elsewhere [6,9,12]. Additionally, there are other
potential explanations for the association between
ciprofloxacin resistance and broad-spectrum
cephalosporins resistance; these include active efflux and
outer membrane protein alterations [16]. For
ciprofloxacin resistance in K. pneumoniae and E. coli,
transfer of the same plasmid has been suggested as a fur-
ther possible explanation for the coexistence of the two
resistance mechanisms [17,18]. Plasmid-mediated
ciprofloxacin resistance has recently been reported in such
strains [19,20]. Furthermore, a new plasmid-mediated
quinolone resistance gene, qnrC, was reported in a clinical
isolate of P. mirabilis [21]. However, the basis for the
ciprofloxacin resistance combined with ESBL production
is not yet fully understood. Further investigation of the
possible mechanisms is needed.
Prior therapy with fluoroquinolones is an important risk
factor for ciprofloxacin resistance in Gram-negative bacilli
[22,23]. In this regard, we were unable to assess possible
associations between ciprofloxacin resistance and prior
use of antibiotics in this study because of the small num-
ber of cases. Additionally, we sought to delineate the clini-
cal features of Proteus bacteremia, rather than focusing on
microbiological analyses, and so did not characterize
ESBL types. Thus, misclassification with regard to ESBL
production may have been possible in several patients.
Finally, because our study was conducted in a large ter-
tiary-care hospital, the results may not necessarily be
applicable to other institutions.
In conclusion, our investigation of risk factors for
ciprofloxacin-resistant P. mirabilis bacteremia revealed a
close association between ciprofloxacin resistance and
ESBL production. This association is particularly trouble-
some because the therapeutic options for serious infec-
tions caused by ESBL-producing P. mirabilis are severely
restricted.
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